Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
Rev. bras. hematol. hemoter
; 36(1): 54-59, Jan-Feb/2014.
Article
em En
| LILACS
| ID: lil-703702
Biblioteca responsável:
BR408.1
ABSTRACT
Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.
Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Proteínas Tirosina Quinases
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Proteínas de Fusão bcr-abl
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Rev. bras. hematol. hemoter
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2014
Tipo de documento:
Article